Biocon Q3 FY26 Earnings: Revenue Up 9% YoY to ₹4,173 Cr, Net Profit Jumps 844% YoY to ₹124 Cr
Biocon Limited reported Q3 FY26 results with revenue from operations at ₹4,173 crore (up 9% YoY). Core EBITDA increased by 21% YoY to ₹1,221 crore. Net Profit (Before exceptional items) surged 844% YoY to ₹124 crore. The company is focused on sustainable growth and margin expansion.
The strong financial results, including significant profit growth and positive operational updates, are likely to have a material positive impact on investor sentiment and the company's stock.
The company reported significant year-on-year growth in revenue and a substantial jump in net profit, indicating strong financial performance.
Biocon Limited announced its financial results for the third quarter of Fiscal Year 2026 (Q3 FY26), reporting a significant year-on-year (YoY) increase in revenue and net profit. The company's revenue from operations grew by 9% YoY to ₹4,173 crore, while total revenue rose by 11% YoY to ₹4,290 crore.
Core EBITDA for the quarter stood at ₹1,221 crore, a 21% increase YoY, with the margin improving to 29% from 26% in the same period last year. EBITDA also saw a 21% YoY jump to ₹951 crore. Profit Before Tax (Before exceptional items) increased by 64% YoY to ₹226 crore. Net Profit (Before exceptional items) surged by 844% YoY to ₹124 crore, and the reported Net Profit was ₹144 crore, up 475% YoY.
The Biosimilars segment reported revenues of ₹2,497 crore, a 9% YoY increase, with Core EBITDA up 37% YoY to ₹895 crore and EBITDA margin at 28%. The Generics segment saw revenues grow by 24% YoY to ₹851 crore, though Core EBITDA decreased by 3% YoY to ₹99 crore. The CRDMO segment's revenue was ₹917 crore, a 3% YoY decrease, with reported EBITDA down 26% YoY to ₹225 crore.
The company highlighted a pivotal transformation underway, focusing on non-communicable diseases and a unified global biopharma platform post Biocon Biologics integration. Major capex is largely behind, with operating leverage beginning to play out, transitioning towards sustainable growth and margin expansion. The presentation for the Q3 FY26 Earnings Call was conducted on February 13, 2026.
What to do with a filing like this
Biocon Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Biocon Limited. Read the original for the full detail.